2020 - A Year Full Of Potentials, page-245

as I understand it.....it was a investigator initiated trial, that was allowed to occur based on phase 3 results of remestemcel-L to investigate extending the application from acute treatments to also include chronic treatments.

so I have no idea what phase level that is...not even going to pretend I do.

but "post-phase3", as I think they get a free pass as part of the extended access process?

i'm probably wrong, as don't have a full grasp ( and no way have I ever claimed to be a expert) ….but to me sounds promising to be alread exploring and having good results with extended applications.

@Doug Diamond if they could merge their success with CYP's manufacturing process.... would be a behemoth of a company then...be scary the end results...